Showing 8341-8350 of 8791 results for "".
- Rosacea Survey: Emotional Impact of Rosacea as Significant and Visible Signshttps://practicaldermatology.com/news/20140116-rosacea_survey_emotional_impact_of_rosacea_as_significant_and_visible_signs/2459371/The emotional impact of rosacea is often substantial regardless of subtype or severity, according to results of a new survey of 1,675 rosacea patients conducted by the National Rosacea Society. Among survey respondents who suffer from the facial redn
- Alma Lasers Debuts its 2014 Webinar Serieshttps://practicaldermatology.com/news/20140116-alma_lasers_debuts_its_2014_webinar_series/2459372/In a complimentary webinar series, industry experts will showcase their success building local market awareness to drive practice results. Spearheaded by Alma Lasers , the informative ses
- Daniel Siegel, MD Appointed to Board of Directors for Caliber Imaging & Diagnosticshttps://practicaldermatology.com/news/20140113-daniel_siegel_md_appointed_to_cabilber_imaging__diagnostics_board_of_directors/2459374/Caliber Imaging & Diagnostics, formerly Lucid, Inc., appointed Daniel Mark Siegel, MD to its Board of Directors, effective immediately. This increases the number of Board members to eight. Dr. Siegel is Clinical Professor of Dermatology at SUNY Downstate Medical Center (State Univ
- FDA Approves Combination Use of GSK's Mekinist® (trametinib) and Tafinlar® (dabrafenib)https://practicaldermatology.com/news/20140109-fda_approves_combination_use_of_gsks_mekinist_trametinib_and_tafinlar_dabrafenib/2459375/GlaxoSmithKline plc [LSE/NYSE: GSK] has received FDA approval of Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma or metastatic melanoma with BRAF V600E or V600K mutation
- Suneva Medical Announces 12-Month Safety Results From Artefill® Acne Scar Studyhttps://practicaldermatology.com/news/20140107-suneva_medical_announces_12-month_safety_results_from_artefill_acne_scar_study/2459379/Suneva Medical Inc. announced the 12-month follow-up data from its randomized, double-blinded, multi-center, Pivotal acne scar investigational study evaluating the safety and efficacy of ArteFillâ, a dermal filler, to treat acne scars.
- Wrinkle remover Revance files for $86 million IPOhttps://practicaldermatology.com/news/20140106-wrinkle_remover_revance_files_for_86_million_ipo/2459380/Revance Therapeutics Inc., a developer of next-generation versions of skin wrinkle eraser Botox, is seeking $86.25 million in an initial public offering.
- NYC's Eric Schweiger, MD Launches Book on Acne Treatmenthttps://practicaldermatology.com/news/20131230-nycs_eric_schweiger_md_launches_book_on_acne_treatment/2459384/New York City dermatologist Eric Schweiger, MD has launched his new book: 100 Acne Tips & Solutions: The Clear Clinic Guide to Perfect Skin, available December 2013 on
- Acneiform Eruptions Examined in New Bookhttps://practicaldermatology.com/news/20131223-acneiform_eruptions_examined_in_new_book/2459387/A new book that addresses the differential diagnosis of acne vulgaris and treatment of acne-like condition is now available through Springer. Acneiform Eruptions in Dermatology, edited by Practical Dermatology Board Member Joshua A. Zeichner, MD, offers expert guidance on acne and syst
- Theradome Laser Helmet Launches for At-home Treatment of Hair Losshttps://practicaldermatology.com/news/20131219-theradome_laser_helmet_launches_for_at-home_treatment_of_hair_loss/2459389/Theradome Laser Helmet LH80 PRO, the first FDA and over-the-counter cleared, wearable laser hair restoration treatment, is now available. Developed for in-home use and designed for patients suffering from the effects of thinning hair and Androge
- Syneron's Home-Use Hair Removal Systems Receive Expanded Indicationhttps://practicaldermatology.com/news/20131219-synerons_home-use_hair_removal_systems_receive_expanded_indication/2459390/The FDA has granted Syneron Medical Ltd. and Iluminage Beauty an expanded indication for me™ brand of home-use hair removal systems. The systems, which utilize Syneron's proprietary elos technology, are now indicated for permanent reduction in hair growth. The me™ brand is owned and sold by Iluminag